UK authorized Regeneron antibody cocktail to prevent and treat acute COVID-19 infection
On Aug. 20, 2021, Regeneron announced that the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency had…
On Aug. 20, 2021, Regeneron announced that the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency had…
On Aug. 19, 2021, the University of Oxford reported that obtaining two vaccine doses remained the most effective…
On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…
On Jul. 29, 2021, SIGA Technologies announced that it had entered into a collaboration with Oxford University in…
On Jul. 29, 2021, Cocrystal Pharma announced that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed…
On Jul. 28, 2021, GlaxoSmithKline and Vir Biotechnology announced they had signed a Joint Procurement Agreement with the…
On Jul. 9, 2021, Humanigen announced its submission for Marketing Authorization for lenzilumab in COVID-19, begun in Jun….
On Jul. 8, 2021, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human…
On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…
On Jun. 30, 2021, SIGA Technologies announced that it had provided TPOXX (tecovirimat) to Liverpool University Hospitals NHS…
On May 27, 2021, Sanofi and GlaxoSmithKline started enrolment in their Phase 3 clinical study to assess the…
On May 21, 2021, Moderna announced that the Ministry of Food and Drug Safety of South Korea (MFDS)…
On May 21, 2021, Novavax announced that the full results from the Phase 3, randomized, observer-blinded, placebo-controlled trial…
On May 21, 2021, Novavax announced participation in a mix-and-match (vaccine interchangeability) COVID-19 vaccine booster trial that led…
On Mar. 22, 2021, Oxford University announced that a Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted…
On Mar. 11, 2021, Novavax announced final efficacy of 96.4% against mild, moderate and severe disease caused by…
On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in…
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
On Jan. 26, 2021, OraSure Technologies announced that Chronomics had selected the OMNIgene-ORAL (OME-505) saliva collection device as…
On Jan. 25, 2021, Moderna announced results from in vitro neutralization studies of sera from individuals vaccinated with…
On Jan. 14, 2021, Twist Bioscience announced that it had started shipping its new synthetic RNA reference controls,…
On Jan. 11, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel – a molecular diagnostic test that detects…
On Jan. 8, 2021, the FDA alerted clinical laboratory staff and health care providers that it was monitoring…
On Jan. 8, 2021, the COVID-19 vaccine developed by Moderna has today been given regulatory approval for supply…
On Jan. 4, 2021, a research partnership between scientists at Scripps Research and UC San Diego found the…
On Dec. 21, 2020, the WHO reported that authorities of the United Kingdom of Great Britain and Northern…
On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…